The stock of Neurocrine Biosciences, Inc. (NBIX) has seen a -2.03% decrease in the past week, with a 1.19% gain in the past month, and a 2.82% flourish in the past quarter. The volatility ratio for the week is 2.97%, and the volatility levels for the past 30 days are at 2.77% for NBIX. The simple moving average for the past 20 days is -0.40% for NBIX’s stock, with a 11.34% simple moving average for the past 200 days.
Is It Worth Investing in Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Right Now?
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has a price-to-earnings ratio that is above its average at 38.32x. The stock has a 36-month beta value of 0.36. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NBIX is 98.39M, and at present, short sellers hold a 1.89% of that float. On May 27, 2024, the average trading volume of NBIX was 845.69K shares.
NBIX) stock’s latest price update
The stock of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has decreased by -0.79 when compared to last closing price of 140.51. Despite this, the company has experienced a -2.03% fall in its stock price over the last five trading sessions. prnewswire.com reported 2024-05-21 that SAN DIEGO, May 21, 2024 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® (valbenazine) capsules in the Journal of Clinical Psychopharmacology. The analysis assessed long-term outcomes relevant to the real-world management of tardive dyskinesia (TD) and demonstrated that nearly all study participants met the threshold for clinically meaningful improvements in TD symptom severity by Week 48.
Analysts’ Opinion of NBIX
Many brokerage firms have already submitted their reports for NBIX stocks, with Wells Fargo repeating the rating for NBIX by listing it as a “Overweight.” The predicted price for NBIX in the upcoming period, according to Wells Fargo is $170 based on the research report published on April 24, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see NBIX reach a price target of $127. The rating they have provided for NBIX stocks is “Neutral” according to the report published on December 13th, 2023.
Deutsche Bank gave a rating of “Buy” to NBIX, setting the target price at $136 in the report published on December 12th of the previous year.
NBIX Trading at 0.52% from the 50-Day Moving Average
After a stumble in the market that brought NBIX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.05% of loss for the given period.
Volatility was left at 2.77%, however, over the last 30 days, the volatility rate increased by 2.97%, as shares surge +2.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.17% upper at present.
During the last 5 trading sessions, NBIX fell by -2.03%, which changed the moving average for the period of 200-days by +37.46% in comparison to the 20-day moving average, which settled at $140.13. In addition, Neurocrine Biosciences, Inc. saw 5.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NBIX starting from POPS RICHARD F, who sale 2,100 shares at the price of $141.84 back on May 17 ’24. After this action, POPS RICHARD F now owns 31,611 shares of Neurocrine Biosciences, Inc., valued at $297,860 using the latest closing price.
Sharp Shalini, the Director of Neurocrine Biosciences, Inc., sale 1,106 shares at $141.90 during a trade that took place back on May 17 ’24, which means that Sharp Shalini is holding 994 shares at $156,943 based on the most recent closing price.
Stock Fundamentals for NBIX
Current profitability levels for the company are sitting at:
- 0.24 for the present operating margin
- 0.98 for the gross margin
The net margin for Neurocrine Biosciences, Inc. stands at 0.19. The total capital return value is set at 0.17. Equity return is now at value 18.16, with 12.68 for asset returns.
Based on Neurocrine Biosciences, Inc. (NBIX), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is 102.26.
Currently, EBITDA for the company is 416.1 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 7.15. The receivables turnover for the company is 4.4for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.52.
Conclusion
To sum up, Neurocrine Biosciences, Inc. (NBIX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
